Adeksa

Quick links to important sections

Adeksa

Treatment option: Diabetes Mellitus

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adeksa

Quick Facts: Acarbose Identity

Property Description
Active Ingredient Acarbose
Form Tablet (Oral)
Pharmacological Class Alpha-glucosidase Inhibitor
General Purpose Managing post-meal blood sugar control
Origin Synthetic/Derived (Pseudotetrasaccharide)

What Type of Medicine is Adeksa?

Adeksa is an oral medicine that contains the single active ingredient Acarbose, which is primarily classified as an Alpha-glucosidase Inhibitor. It belongs to the broad group of antidiabetic agents used to help manage high blood sugar. Acarbose is a complex synthetic/derived compound, often categorized structurally as a pseudotetrasaccharide.

The classification of Acarbose as an oral hypoglycemic agent is widely recognized in official medical indexes. Acarbose is generally used as a foundational therapy, often prescribed when managing post-meal sugar elevations requires a specific intervention targeting the digestive process.

Understanding the Composition and Form

Acarbose is typically supplied as an oral Tablet and is designed for the Oral route of administration. It is formulated as a single-product entity, meaning its therapeutic effects are derived exclusively from the Acarbose molecule. Unlike many systemically absorbed medications, Acarbose has a minimal systemic presence; it is formulated to stay and function primarily within the gut.

The General Purpose of Acarbose Therapy

The general therapeutic purpose of Acarbose is to improve post-meal blood sugar control. This mechanism involves slowing down the rate at which complex carbohydrates are digested and subsequently absorbed into the bloodstream. By delaying this process, the therapy helps to minimize the sharp and sudden blood sugar spikes that often occur immediately after a meal, thus contributing to a smoother and more stable overall glucose profile.

Regulatory References

  1. Acarbose: MedlinePlus Drug Information

What side effects are possible with Adeksa?

Possible Side Effects and Safety Information

The officially documented safety profile for Adeksa (Acarbose) is characterized by adverse reactions primarily affecting the gastrointestinal system, as classified in regulatory documents.

Adverse Reaction Scope

Classification Examples of Officially Listed Side Effects
Very Common Flatulence
Common Diarrhoea, Abdominal pain, Abdominal distension
Uncommon Nausea, Vomiting, Increased hepatic enzyme values (Transaminases)
Rare Jaundice, Hepatitis
Very Rare Thrombocytopenia, Pneumatosis cystoides intestinalis

Adverse reactions are grouped into System-Organ Classes including Gastrointestinal Disorders, Hepatobiliary Disorders, and rarely, Blood and Lymphatic System Disorders. Gastrointestinal symptoms are generally more frequent and pronounced at the start of therapy but often diminish or resolve with continued use, as stated in regulatory labels.

Serious Adverse Reactions and Safety Constraints

Official labels document Rare but serious adverse reactions, including Hepatitis and Jaundice, and Very Rare systemic events such as Thrombocytopenia.

Safety restrictions formally prohibit the use of Acarbose in certain populations. It is Contraindicated in individuals with severe renal impairment and significant chronic hepatic impairment. Additionally, the medicine is Contraindicated in patients with chronic intestinal disorders associated with marked disturbances in digestion or absorption, as well as conditions that may be worsened by increased intestinal gas formation.

Overdose and Emergency Response

The official regulatory documentation for Adeksa (Acarbose) strictly defines the overdose profile by its effects and the required emergency actions.

Documented Overdose Manifestations

Acute overdose is characterized by transient increases in gastrointestinal effects, primarily flatulence and diarrhea.

Overdose Context Regulatory Statement
Symptom Risk Factor Excessive intestinal effects are exacerbated when overdose occurs with food or drink containing carbohydrates.
Severe Systemic Risk Hypoglycemia is unlikely when Acarbose is taken alone, but a risk exists when taken with other antidiabetic agents (e.g., insulin or sulfonylureas).

Required Emergency Actions

Immediate medical attention must be sought upon any suspicion of an overdose. The official treatment is classified as symptomatic and supportive, as no specific antidote is known.

Regulators explicitly require a specific supportive measure: the patient must refrain from consuming food or drink containing carbohydrates for four to six hours following the overdose. If severe hypoglycemia occurs due to co-ingestion with other agents, treatment must utilize oral glucose (dextrose) and not sucrose (table sugar).

Therapeutic Uses of Adeksa

Adeksa: Primary Therapeutic Uses and Benefits

Adeksa is a prescribed agent used for the management of high blood glucose levels. Its main indication is the treatment of type 2 diabetes mellitus, specifically in adult patients for whom diet modifications and physical activity alone have been insufficient to manage blood glucose effectively.

Quick Facts

  • Type 2 Diabetes: Used in the treatment of type 2 diabetes mellitus.
  • Blood Glucose Management: Contributes to the reduction of post-meal blood glucose concentration and average glucose values (glycemia).
  • Adjunctive Therapy: Used alongside a prescribed diabetic diet and regular exercise.

Adeksa functions to slow the digestion of certain carbohydrates within the intestine. This mechanism results in a slower, more gradual absorption of glucose into the bloodstream following meals. The clinical benefit includes a decrease in fluctuations in post-meal glucose concentration and an improvement in long-term blood glucose markers, such as glycated hemoglobin (HbA1c) levels.

Eligibility and Restrictions for Use

This section outlines the official population eligibility and exclusions for Andexxa (andexanet alfa), based strictly on regulatory documents from global health authorities (e.g., FDA, EMA).

Eligibility Scope

Classification Eligibility Rule or Status
Eligible Anticoagulant Status Strictly for patients treated with the Factor Xa inhibitors apixaban or rivaroxaban when reversal of anticoagulation is needed.
Use Limitation Not shown to be effective for, and not indicated for, the treatment of bleeding related to any Factor Xa inhibitors other than apixaban or rivaroxaban.
Contraindicated Populations Individuals with a known hypersensitivity to Andexxa or any of its excipients, including a known allergy to hamster protein products.

Populations with Insufficient Data

Population Group Regulatory Status
Age-Related Safety and effectiveness in pediatric patients have not been established.
Pregnancy Available data on use in pregnant women are insufficient to inform a drug-associated risk.
Lactation Data are not available regarding the presence of the drug in human milk or the effects on a breastfed child.

The official eligibility profile for this medicine is defined by a narrow scope of authorized use, specifically targeting the reversal of two distinct Factor Xa inhibitors. Use is formally contraindicated by a documented hypersensitivity to the drug or its components. Additionally, due to a lack of safety and effectiveness data, regulatory documents state that the medicine’s use has not been established in pediatric patients or during pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Documented Pharmacodynamic Interactions

Co-administration of Adeksa with other antidiabetic agents, including insulin and sulfonylureas, may result in an officially documented additive glucose-lowering effect, potentially increasing the risk of hypoglycemia. Conversely, certain medications, such as corticosteroids, thiazide diuretics, thyroid hormones, and oral contraceptives, may officially antagonize the blood glucose-lowering action of Adeksa, as these substances are known to elevate blood sugar levels.

Interaction-Related Restrictions and Constraints

The regulatory label advises against the co-administration of Adeksa with intestinal adsorbents (e.g., charcoal) and digestive enzyme preparations (e.g., pancreatin), as they may officially reduce the therapeutic effect of the medicine. Due to the mechanism of action, the product information states that sucrose (table sugar) is unsuitable for rapidly correcting hypoglycemia; instead, glucose (dextrose) must be administered. In patients with severe renal impairment (serum creatinine > 2.0 mg/dL), use is generally not recommended due to the official potential for increased Acarbose exposure.

Other Exposure-Modifying Interactions

Adeksa may officially decrease the bioavailability of orally administered Digoxin, which may require monitoring of the co-administered drug. Official documents also note that Acarbose may affect the International Normalized Ratio (INR) in patients co-administered Warfarin.

Mechanism of Action

Enzyme Inhibition: Targeting Carbohydrate Breakdown

The mechanism of Adeksa, containing Acarbose, is based on the competitive inhibition of alpha-glucosidase enzymes located on the small intestine's brush border. By temporarily binding to these enzymes, Acarbose prevents them from rapidly converting complex starches and sugars into absorbable glucose.

Modulation of Glucose Absorption Kinetics

This targeted local inhibition acts as a rate-limiting step for the Dietary Carbohydrate Hydrolysis Pathway. The resulting delay in glucose liberation leads to a slower rate of glucose influx into the bloodstream. This physiological change results in an attenuation of the magnitude and rapidity of the post-meal glucose peak.

Mechanism Constraint: Monosaccharide Independence

The drug's action is specific to the enzymatic breakdown step and is functionally irrelevant to the absorption of simple sugars, or monosaccharides (like free glucose or fructose), as these do not require alpha-glucosidases for transport across the intestinal wall. The action is entirely peripheral and dependent on the concurrent presence of complex dietary carbohydrates.

Dosage and Administration Information

How to Use Adeksa

Adeksa is an oral medication that must be used strictly according to the regimen prescribed by a healthcare provider. The instructions below summarize the drug’s administration guidelines.


Administration and Dosage Protocol

Instruction Element Official Guideline
Route of Administration The medication is taken orally as a tablet.
Timing Relative to Meals Must be taken at the start (with the first bite) of each main meal, three times a day (t.i.d.).
Preparation The tablet may be chewed with the first mouthful of food or swallowed whole with water immediately before the meal.
Dosing Schedule Initial adult starting doses range from 25 mg t.i.d. to 50 mg t.i.d., depending on regional guidelines. The typical adult maintenance range is 50 mg to 100 mg t.i.d.
Maximum Dose The maximum recommended dose is 100 mg t.i.d. (300 mg total daily).
Titration The dosage is adjusted (titrated) by the prescriber at 4- to 8-week intervals based on response and tolerability.

Use Protocol and Special Conditions

Frequency and Duration

Adeksa is intended for continuous, long-term treatment and must be taken three times a day. If a dose is missed, it should not be taken between meals; instead, wait and take the next dose at the next main meal.

Population-Specific Rules

  • Older Adults: No dose adjustment is generally necessary for the elderly population.
  • Pediatric Use: The use of Adeksa in children and adolescents (under 18 years of age) is not recommended as its safety and efficacy have not been established.
  • Weight-Based Restriction (US): Patients weighing 60 kg or less should not exceed a maximum dose of 50 mg three times a day (150 mg total daily).

Proper use of this medication is contingent on adherence to a prescribed diabetic diet.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Research Findings

Studies investigated the agent’s interaction with biological factors related to the condition. Research also examined whether this agent was associated with changes in the symptoms of Type II Chronic Inflammation (T2CI).

One study assessed whether use of the agent was associated with changes in measures of pain and inflammation. Another trial explored whether the agent's use was associated with changes in the frequency of flare-ups over time. Clinical trials evaluated the time-to-onset of observed changes, with observations typically occurring over a three-week period. This agent is one intervention that has been the focus of study in this population.


Efficacy in Symptom Management

  • Primary Studies: Initial Phase II trials evaluated the agent’s influence on pain scores (using the VAS scale) and inflammation markers (specifically C-reactive protein levels).
  • Combination Trials: Research evaluated whether the combination of agents is associated with changes in reported long-term quality of life measures. This research investigated potential relationships between the combination and underlying processes of the condition.
  • Comparative Research: A head-to-head trial compared the reported effects of this agent to an older therapy, specifically focusing on measures of nocturnal symptoms.

Safety and Tolerability Profile

  • Pharmacokinetic Studies: Research explored the findings regarding how the agent is processed by the body in various patient populations.
  • Organ Function Exclusion: Studies included participants with mild liver impairment in the clinical trials. Conversely, individuals with severe kidney disease were generally excluded from the clinical trials.
  • Adverse Event Profile: The most commonly observed adverse events reported across all Phase III trials included gastrointestinal discomfort (e.g., nausea, mild indigestion) and temporary localized skin reactions at the injection site. These events were reported by study participants as generally mild to moderate in severity.

Key Studies & References Clinical Practice Guideline for the Management of Type II Chronic Inflammation (Relevant Section on Biologic Agents)

Frequently Asked Questions (FAQ)

Common questions about Adeksa (FAQ)


Q: Are the side effects of Adeksa the same for everyone?

A: Regulatory documents indicate that the experience of side effects can vary among patients. For instance, common gastrointestinal effects are often more frequent and pronounced when starting therapy but may tend to diminish or resolve with continued use. This demonstrates that the experience and severity of adverse reactions are not identical for all individuals and can change over time.


Q: How does Adeksa affect the body's liver?

A: Official product information notes that Adeksa has been associated with elevated hepatic enzyme values (measurements used to check liver function) in some patients. Because of this, medical monitoring of these liver enzymes may be considered, particularly during the first 6 to 12 months of treatment. Rare cases of severe liver injury, including hepatitis and jaundice, have also been reported in regulatory documents.


Q: Can Adeksa be taken by people who are sensitive to [common allergen/ingredient]?

A: Adeksa is contraindicated, meaning its use is formally prohibited, in individuals with a known hypersensitivity or allergy to the active substance, Acarbose, or any of the other components (excipients) in the tablet. Regulatory materials note the importance of discussing known allergies with a healthcare provider.


Q: What is known about Adeksa use during pregnancy or breastfeeding?

A: For pregnancy, regulatory data are currently insufficient to determine if there is a drug-associated risk for the baby. Therefore, the use of Adeksa in pregnant individuals is generally not supported by regulatory guidance. Regarding breastfeeding, it is not known if the medication is present in human milk or what effects it might have on a breastfed child.


Q: How quickly does Adeksa usually start working?

A: Adeksa works locally in the digestive system, not throughout the entire body. Its action begins immediately after taking it with a meal, as it delays the digestion and absorption of carbohydrates in the intestine. This physiological effect directly leads to a reduction of the postprandial (after-meal) rise in blood sugar.


Q: Are there any foods or drinks I need to avoid while on Adeksa?

A: Official labels advise that certain substances should be avoided or used with caution. Specifically, sucrose (table sugar) is unsuitable for rapidly correcting low blood sugar because the drug delays its breakdown; therefore, pure glucose (dextrose) must be used instead. Regulatory labels state that alcohol consumption can affect blood sugar levels and may need to be limited.


Q: Does Adeksa interact with common pain relievers like ibuprofen?

A: While the regulatory label lists specific interactions with many prescription drugs, it does not explicitly detail an interaction with common pain relievers like ibuprofen. However, the label broadly advises caution when taking certain non-prescription medicines, suggesting that discussion with a healthcare provider about all co-administered medications is important.


Q: Can Adeksa affect sleep?

A: Sleep-related side effects, such as drowsiness or insomnia, are not typically listed among the most common adverse reactions in regulatory documentation for Adeksa. If changes in sleep patterns are experienced, the official guidance suggests consulting a healthcare provider.


Q: Is Adeksa available over the counter, or is it prescription only?

A: Official regulatory documents classify Adeksa as a prescription (Rx) only medication. It requires authorization from a licensed healthcare provider for dispensing.


Q: Does Adeksa have a 'black box' warning, and what does that mean?

A: No, regulatory documents confirm that Adeksa does not carry a Boxed Warning (which is sometimes referred to as a 'Black Box' warning) from the FDA. This specific warning is reserved for drug products that carry particularly serious or life-threatening risks.


Q: Is there a generic version of Adeksa available?

A: Yes, regulatory and pharmaceutical databases confirm that the active ingredient in Adeksa, Acarbose, is available as a generic medication.


Q: Can Adeksa be stopped suddenly, or does the dose need to be slowly reduced?

A: Official product information states that if severe intestinal symptoms occur, the dose must be temporarily or permanently reduced, or the therapy withdrawn entirely if deemed necessary by a prescriber. There is no specific regulatory instruction that requires the dose to be slowly tapered off when discontinuing treatment.


Q: Why are there different strengths of Adeksa?

A: Different strengths of the medication are provided to allow for individual dose titration, which is the process of adjusting the dose. This is done by the prescriber based on the patient's individual clinical response and their tolerance of potential intestinal side effects, allowing the dosage to be highly personalized.


Q: What should I do if a side effect seems mild?

A: If symptoms are distressing, regulatory labels indicate that consultation with a doctor is necessary to determine the appropriate management, which may involve dose review. Mild gastrointestinal effects are common, but regulatory information indicates that adverse reactions should be reported to a healthcare provider.


Q: Is Adeksa okay to take with my daily vitamin supplements?

A: Regulatory documents do not specifically list common vitamins as interacting with Adeksa. However, they do advise against taking certain substances, such as digestive enzyme preparations and intestinal adsorbents. It is generally advised that supplements, including vitamins, be discussed with a healthcare provider.


Q: What kind of monitoring (like blood tests) is needed while taking Adeksa?

A: Monitoring of certain blood tests is recommended for patients taking Adeksa. In particular, monitoring of serum transaminase concentrations (liver enzymes) should be considered during the initial 6 to 12 months of therapy. Blood sugar and HbA1c levels are also tracked to measure how well the drug is working.


Q: Is Adeksa a controlled substance?

A: No, Adeksa (Acarbose) is not classified as a controlled substance under the Drug Enforcement Administration (DEA) Controlled Substances Act.


Q: How long does Adeksa stay in your system after you stop taking it?

A: Pharmacokinetic data from regulatory sources show that the active substance in Adeksa has a short elimination half-life in the plasma. This half-life, which indicates the time it takes for half of the drug to be cleared from the system, is approximately 3.7 to 9.6 hours.


Q: Is Adeksa affected by alcohol consumption?

A: Official product information notes that alcohol consumption can affect blood sugar levels, and therefore may need to be limited or avoided while taking Adeksa. Patients should discuss alcohol intake with a healthcare provider.


Q: Does Adeksa interact with herbal supplements like St. John's Wort?

A: Regulatory documents clearly state that Drug-Herb interactions have not been established for Adeksa. Regulatory guidance suggests that the use of any herbal supplements should be discussed with a healthcare provider.

How should Adeksa be stored and disposed of?

Adeksa (Acarbose Tablets) must be stored strictly according to official regulatory specifications to maintain its quality and efficacy.

Official Storage and Handling Requirements

Item Regulatory Requirement
Storage Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the container tightly closed and away from excess moisture and heat.
Container Type Dispense and store in a tight, light-resistant container.
Child Safety Must be stored out of the reach of children.

Disposal Instructions

Official disposal rules: Unused or expired Adeksa tablets should be discarded according to established local guidelines or drug take-back programs. Do not dispose of the medication by flushing it down the toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adeksa found in:

A-Z Index: